About Revolution Medicines, Inc. - Common Stock (RVMD)
Revolution Medicines Inc is a biotechnology company focused on developing innovative therapies to target difficult-to-treat cancers. The company is dedicated to advancing the field of precision medicine, leveraging its proprietary drug discovery platforms to explore new approaches to inhibit cancer-causing pathways. Through rigorous research and clinical trials, Revolution Medicines aims to bring forward novel treatments that not only address the complexities of tumor biology but also improve the effectiveness and safety of cancer care for patients. Their commitment to scientific excellence and collaboration positions them as a forward-thinking leader in the oncology space. Read More
Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data.
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines’ clinical-stage RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldonrasib (RMC-9805) and G12C-selective inhibitor elironrasib (RMC-6291), in combination with Summit Therapeutics’ ivonescimab, a PD-1 / VEGF bispecific antibody.
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.
